Background: In the wake of the emerging development of biologics in atopic dermatitis (AD), herpes zoster (HZ) infection has been reported as a treatment-related adverse event.
Objectives:
This study aims at investigating the association between AD and HZ, and the risk factors within.
Methods:
28,677 participants with AD from the Taiwan National Health Insurance Research Database 2000–2015 were enrolled. Risk of HZ infection was compared in the study cohort (with AD) and the control cohort (without AD). Further analyses were conducted in gender-, age-, and treatment strategy-stratified subgroups.
Results:
Significantly higher adjusted hazard ratios (aHRs) of HZ infection were revealed in AD patients (aHR = 2.303, P < 0.001), and remained this trend in gender- and age-stratified models. All AD groups, irrespective of the treatment type, had higher aHRs (AD without systemic treatment: aHR = 2.356, P < 0.001; AD with systemic treatment: aHR = 2.182, P < 0.001) compared with those without AD. However, no differences in HZ risk were shown between each treatment type.
Conclusions:
Risk of HZ infection in AD is higher irrespective of treatment type. Considering that AD per se increases susceptibility to HZ infection, the administration of biologics requires careful considerations.
HendricksAJ, YosipovitchG, ShiVY. Dupilumab use in dermatologic conditions beyond atopic dermatitis—a systematic review. J Dermatolog Treat, 2021; 32(1):19–28; doi: 10.1080/09546634.2019.1689227
3.
Renert-YuvalY, Guttman-YasskyE. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann Allergy Asthma Immunol, 2020; 124(1):28–35; doi: 10.1016/j.anai.2019.10.005
4.
ChovatiyaR, PallerAS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol, 2021; 148(4):927–940; doi: 10.1016/j.jaci.2021.08.009
WollenbergA, ThomsenSF, LacourJP, et al.Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ J, 2021; 14(3):100519; doi: 10.1016/j.waojou.2021.100519
7.
RatchataswanT, BanzonTM, ThyssenJP, WeidingerS, Guttman-YasskyE, PhipatanakulW. Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract, 2021; 9(3):1053–1065; doi: 10.1016/j.jaip.2020.11.034
8.
WerfelT, IrvineAD, BangertC, et al.An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol, 2022; 36(9):1486–1496; doi: 10.1111/jdv.18193
9.
BieberT, ThyssenJP, ReichK, et al.Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol, 2021; 35(2):476–485; doi: 10.1111/jdv.16948
10.
Guttman-YasskyE, TeixeiraHD, SimpsonEL, et al.Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure up 1 and Measure up 2): Results from two replicate double-blind, randomised controlled phase 3 trials. Lancet, 2021; 397(10290):2151–2168; doi: 10.1016/s0140-6736(21)00588-2
11.
GooderhamMJ, FormanSB, BissonnetteR, et al.Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol, 2019; 155(12):1371–1379; doi: 10.1001/jamadermatol.2019.2855
12.
SilverbergJI, SimpsonEL, ThyssenJP, et al.Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol, 2020; 156(8):863–873; doi: 10.1001/jamadermatol.2020.1406
13.
SimpsonEL, FlohrC, EichenfieldLF, et al.Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol, 2018; 78(5):863–871.e11; doi: 10.1016/j.jaad.2018.01.017
14.
DamourA, GarciaM, SeneschalJ, et al.Eczema herpeticum: clinical and pathophysiological aspects. Clin Rev Allergy Immunol, 2020; 59(1):1–18; doi: 10.1007/s12016-019-08768-3
WanJ, ShinDB, SyedMN, et al.Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: A population-based cohort study. Br J Dermatol, 2022; 186(4):664–672; doi: 10.1111/bjd.20887
17.
ChovatiyaR, SilverbergJI. Association of herpes zoster and chronic inflammatory skin disease in US inpatients. J Am Acad Dermatol, 2021; 85(6):1437–1445; doi: 10.1016/j.jaad.2019.12.073
18.
RenZ, SilverbergJI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections. Dermatitis, 2020; 31(2):157–164;doi: 10.1097/der.0000000000000526
19.
RystedtI, StrannegardIL, StrannegardO. Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol, 1986; 114(5):575–582; doi: 10.1111/j.1365–2133.1986.tb04064.x
20.
SongJG, SuhMK, HaGY, et al.Herpes zoster in children and adolescents: a 10-year retrospective study at a single institution. Korean J Dermatol, 2016; 54(8):628–633.
21.
HsiehCY, SuCC, ShaoSC, et al.Taiwan's National Health Insurance Research Database: past and future. Clin Epidemiol, 2019; 11:349–358; doi: 10.2147/clep.S196293
22.
KaoWH, HongJH, SeeLC, et al.Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan. Pharmacoepidemiol Drug Saf, 2018; 27(10):1060–1066; doi: 10.1002/pds.4267
23.
HsiehCY, ChenCH, LiCY, et al.Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc, 2015; 114(3):254–259; doi: 10.1016/j.jfma.2013.09.009
24.
IcenM, CrowsonCS, McEvoyMT, et al.Potential misclassification of patients with psoriasis in electronic databases. J Am Acad Dermatol, 2008; 59(6):981–985; doi: 10.1016/j.jaad.2008.08.034
25.
CharlsonME, CarrozzinoD, GuidiJ, et al.Charlson comorbidity index: a critical review of clinimetric properties. Psychother psychosom, 2022; 91(1):8–35; doi: 10.1159/000521288
26.
TommasiC, BreuerJ. The biology of varicella-zoster virus replication in the skin. Viruses, 2022; 14(5); doi: 10.3390/v14050982
WilliamsonS, MerrittJ, De BenedettoA. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol, 2020; 182(1):47–54; doi: 10.1111/bjd.17896
29.
HataTR, KotolP, BoguniewiczM, et al.History of eczema herpeticum is associated with the inability to induce human β-defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol, 2010; 163(3):659–661; doi: 10.1111/j.1365–2133.2010.09892.x
30.
CrackLR, JonesL, MalavigeGN, et al.Human antimicrobial peptides LL-37 and human β-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus. Clin Exp Dermatol, 2012; 37(5):534–543; doi: 10.1111/j.1365–2230.2012.04305.x
HowellMD, GalloRL, BoguniewiczM, et al.Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity, 2006; 24(3):341–348; doi: 10.1016/j.immuni.2006.02.006
33.
SenN, SungP, PandaA, ArvinAM. Distinctive roles for type I and type II interferons and interferon regulatory factors in the host cell defense against varicella-zoster virus. J Virol, 2018; 92(21); doi: 10.1128/jvi.01151-18
34.
NovakN. An update on the role of human dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol, 2012; 129(4):879–886; doi: 10.1016/j.jaci.2012.01.062
35.
TsoiLC, RodriguezE, StölzlD, et al.Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol, 2020; 145(5):1406–1415; doi: 10.1016/j.jaci.2019.11.047
36.
YuHR, ChenRF, HongKC, et al.IL-12-independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus. Eur J Immunol, 2005; 35(12):3664–3672; doi: 10.1002/eji.200526258
37.
BaumrinE, Van VoorheesA, GargA, et al.A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol, 2019; 81(1):102–110; doi: 10.1016/j.jaad.2019.03.017
PowellR, HileG, LoweL, et al.Herpes zoster infection after topical steroid use in the setting of tumid lupus erythematosus. JAAD Case Rep, 2018; 4(1):107–109; doi: 10.1016/j.jdcr.2017.09.005
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
